To view the PDF file, sign up for a MySharenet subscription.

ASPEN PHARMACARE HOLDINGS LIMITED - Aspens response to the press reports of 14 and 15 April 2017

Release Date: 18/04/2017 08:00
Code(s): APN     PDF:  
Wrap Text
Aspen’s response to the press reports of 14 and 15 April 2017

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
and its subsidiaries (collectively “Aspen” or “the Aspen Group”)

ASPEN’S RESPONSE TO THE PRESS REPORTS OF 14 AND 15 APRIL 2017

In reference to the articles reported in the European press on 14 and 15 April 2017, Aspen Holdings
wishes to comment as follows:

    -    Aspen has clearly demonstrated its commitment to providing quality medicines affordably over
         many years. The supply of the oncology products in question is no exception.

    -    Aspen’s status as a responsible and committed provider of quality, affordable medicines is further
         validated by the role it has played in saving millions of lives across Africa through pioneering and
         supplying generic anti-retroviral medicine in Africa for the treatment of HIV/AIDS.

    -    The content of the reports concern matters that are sub-judice. Out of respect for the integrity
         of ongoing legal processes with European regulators, as well as the court in Italy, Aspen will not
         comment on these public allegations. Instead, Aspen looks forward to the opportunity to
         demonstrate the integrity and legality of its practices in the context of these legal processes.

    -    The oncology portfolio in question generated revenue in the European Union in Aspen’s
         financial year ended 30 June 2016 of €60 million (R963 million). The majority of the revenue
         was from the sale of tablets which have an average price of approximately €2 per tablet. The
         Aspen Group’s total revenue for the year ending 30 June 2016 was R35,6 billion.


Durban
18 April 2017


Sponsor:
Investec Bank Limited

Date: 18/04/2017 08:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story